Anders Ljunggren will support Stuart Gander, who as previously communicated, will take over as Group CEO as of 1 March 2024. Anders Ljunggren will be based in Uppsala and thus work as a strong bridge between Uppsala and the US where Stuart Gander is initially based.

Anders Ljunggren has extensive experience from the healthcare industry, with a focus on diagnostics and medical technology. In recent years, he has led the project organization at Q-linea and has previously worked with, among others, Tobii and GE Healthcare. Anders has a deep knowledge of Q-linea's various departments and is a member of the company's management team.

"I am very much looking forward to starting to work with Stuart and continuing to work with the management team in my new role, with a focus on helping the organization develop to become even better at delivering its projects and commitments according to our strategic plan. Q-linea consists of a team of highly competent people and the work holds a high technical level. It is an environment that I have worked in for many years and feel comfortable in. I am grateful for the trust that the board has given me and am humbled by the challenge that the role of Managing Director entails", says Anders Ljunggren, incoming Managing Director of Q-linea AB.

"I welcome Anders in his new role as leader of Q-linea's Swedish organization. Together with Stuart and others in the management group, they will form a strong team for Q-linea's continued commercialization and development", says Erika Kjellberg Eriksson, Chairman of the board of Q-linea.

For more information, please contact:

Jonas Jarvius, CEO, Q-linea AB
Jonas.Jarvius@qlinea.com
+46 (0) 70-323 77 60

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company's lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

This information is information that Q-linea is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-02-01 10:00 CET.

Attachments

Anders Ljunggren takes office as Managing Director of Q-linea AB on 1 March 2024

© Modular Finance, source Nordic Press Releases